Catalyst Edge · Scanner · Tickers · PFHO
CATALYST DOSSIER · UPDATED 2026-10-20

$PFHO

Unclassified · convergence — · conviction —
Convergence Score
—
Conviction
—
Signals Firing
0
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $PFHO?

PFHO -22 AVOID biotech

Quantitative

  • Revenue (CY2026Q1): $1.5M (-17.6% YoY)
  • Net Income (CY2026Q1): $193.7K (-33.8% YoY)

Catalysts

  • Multi-spoke convergence: 5 convergent signals fired: auto_macro_edgar_fts, auto_macro_nasa_power, auto_macro_ofr_fsi, auto_macro_options_gex, auto_macro_vix_term

Risks

  • Position-sizing discipline: Conviction AVOID (-22 score) — size accordingly; no specific catalyst-fade risk flagged

Bear case

  • Multiple compression: If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis

Sympathy basket (cerebro)

  • BSP via tech r=+0.86 sympathetic (score 13)
  • QTWO via tech r=+0.86 sympathetic (score 13)
  • WTTR via materials r=+0.83 sympathetic (score 14)
  • INHD via materials r=+0.83 sympathetic (score 13)
  • SKHY via semis r=+0.77 sympathetic (score 5)
  • MVIS via semis r=+0.77 sympathetic (score 3)

Signals Firing

No active signals this cycle.
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.